| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Other names | VXA-CoV2-1, VXA-CoV2-1.1-S |
| Routes of administration | Oral |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
 COVID-19 portal |
Vaxart COVID-19 vaccine is a COVID-19 vaccine candidate developed by Vaxart.[1][2][3]
References
- ^ Clinical trial number NCT04563702 for "Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults" at ClinicalTrials.gov
- ^ Clinical trial number NCT05067933 for "Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (VXA-NVV-104)" at ClinicalTrials.gov
- ^ Clinical trial number NCT05067933 for "A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine" at ClinicalTrials.gov
Scholia has a profile for Vaxart COVID-19 vaccine (Q110269782).
This page was last edited on 28 August 2023, at 04:31